Cargando…

IMMU-05. TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS

Immunotherapies have transformed the therapeutic landscape for various cancer indications; currently several preclinical and clinical studies are exploring immune-based therapies for the treatment of central nervous system (CNS) tumors. The recognition of toxicity syndromes and establishment of toxi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahdi, Jasia, Dietrich, Jorg, Straathof, Karin, Roddie, Claire, Scott, Brian, Davidson, Tom Belle, Prolo, Laura, Batchelor, Tracy, Campen, Cynthia, Davis, Kara, Gust, Juliane, Lim, Michael, Majzner, Robbie, Park, Julie, Partap, Sonia, Ramakrishna, Sneha, Richards, Rebecca, Schultz, Liora, Vitanza, Nicholas, Wang, Leo, Mackall, Crystal, Monje, Michelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: Immunology/Immunotherapy - IMMU
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260084/ http://dx.doi.org/10.1093/neuonc/noad073.192

Ejemplares similares

IMMU-12. T CELL SEQUESTRATION IN POSTERIOR FOSSA TUMORS
por: Wilson, Zach, et al.
Publicado: (2023)

IMMU-17. DEVELOPMENT OF AN INTRACRANIAL CANNULA IMPLANTATION SYSTEM FOR SERIAL LOCOREGIONAL CAR T CELL INFUSIONS IN MICE
por: Harvey, Kyra, et al.
Publicado: (2023)

IMMU-01. EVALUATING THE IMPACT OF CAR DESIGN ON THE TUMOR IMMUNE MICROENVIRONMENT AND ANTI-TUMOR RESPONSE IN SYNGENEIC GLIOMA MODELS
por: Haydar, Dalia, et al.
Publicado: (2023)

IMMU-16. IDENTIFICATION OF TUMOR REJECTION ANTIGENS FOR PRECISION ADOPTIVE CELLULAR THERAPY FOR PEDIATRIC GLIOMAS
por: Trivedi, Vrunda, et al.
Publicado: (2023)

IMMU-11. PRECLINICAL HIGH-RISK PEDIATRIC BRAIN TUMOR MODELS FOR IMMUNOTHERAPY: HURDLES AND THE WAY FORWARD
por: Mishra, Deepak, et al.
Publicado: (2023)

IMMU-10. PILOCYTIC ASTROCYTOMAS SHOW EVIDENCE OF INTRINSIC IMMUNE SURVEILLANCE AND ACTIVATION WITHIN THE TUMOR MICROENVIRONMENT
por: Najem, Hinda, et al.
Publicado: (2023)

IMMU-09. DISSECTING THE INTERPLAY BETWEEN THE ENDOGENOUS IMMUNE RESPONSE AND ONCOLYTIC VIRUS THERAPY IN PEDIATRIC BRAIN TUMORS
por: Hoare, Owen, et al.
Publicado: (2023)

IMMU-14. WAKING THE SLEEPING GIANT: TLR7/8 AGONIST TREATMENT STIMULATES TUMOR-ASSOCIATED MYELOID CELLS FOR MEDULLOBLASTOMA IMMUNOTHERAPY
por: Pauneto, Coral Alicea, et al.
Publicado: (2023)

IMMU-02. CMV-EXPANDED T-CELLS IN GLIOBLASTOMA PATIENTS: TRANSLATIONAL RESEARCH
por: Kampers, Linde F C, et al.
Publicado: (2023)

IMMU-13. PRECLINICAL EFFICACY OF MULTI-ANTIGEN (HER2/EGFR806/B7-H3/IL13RA2) TARGETING QUAD-CAR T CELLS AGAINST DIFFUSE MIDLINE GLIOMA
por: Myers, Carrie, et al.
Publicado: (2023)

IMMU-06. SYSTEMIC MRNA VACCINES RESET IMMUNOGENICITY AGAINST DIFFUSE MIDLINE GLIOMA
por: McGuiness, James, et al.
Publicado: (2023)

IMMU-20. EVALUATION OF B7-H3 NANOBODY CAR-T CELLS IN PEDIATRIC GLIOBLASTOMA
por: Fanuzzi, Mia, et al.
Publicado: (2023)

IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
por: Owens, Geoffrey, et al.
Publicado: (2023)

IMMU-23. RESEARCH ON MULTI-ANTIGEN T CELL INFUSION AGAINST NEURO-ONCOLOGIC DISEASE (ReMIND)
por: Cruz, Conrad Russell, et al.
Publicado: (2023)

IMMU-18. TARGETING GD2 IN THALAMIC DIFFUSE MIDLINE GLIOMA WITH TRANSIENT MRNA CAR T CELLS
por: Foster, Jessica, et al.
Publicado: (2023)

IMMU-19. NIVOLUMAB-INDUCED CNS DEMYELINATION IN A 15-YEAR-OLD WITH CLASSIC HODGKIN LYMPHOMA
por: Ramirez, Alejandra, et al.
Publicado: (2023)

IMMU-21. ELUCIDATING THE CELLULAR MECHANISMS OF THERAPEUTIC BENEFIT UNDERLYING ADOPTIVE CELLULAR THERAPY IN MODELS OF GLIOMA
por: Figg, John, et al.
Publicado: (2023)

IMMU-03. IDENTIFICATION OF GENETIC BIOMARKERS TO PREDICT RESPONSE TO HSV-1 G207 AND POLIO:RHINOVIRUS IMMUNOTHERAPY
por: Thompson, Eric, et al.
Publicado: (2023)

IMMU-15. PHASE I TRIAL OF GD2.CART-CELLS AUGMENTED WITH A CONSTITUTIVELY ACTIVE INTERLEUKIN-7 RECEPTOR (C7R) FOR TREATMENT OF HIGH-GRADE PEDIATRIC CNS TUMORS
por: Lin, Frank, et al.
Publicado: (2023)

IMMU-22. ALLOGENEIC NK CELLS SECRETING IL15 AND RESISTANT TO TGF-β Show Antitumor Activity Against Gliobastoma
por: Muniraj, Nethaji, et al.
Publicado: (2023)

IMMU-07. TACEDINALINE (CI994), A CLASS I HDAC INHIBITOR, TARGETS INTRINSIC TUMOR GROWTH AND LEPTOMENINGEAL DISSEMINATION IN MYC-DRIVEN MEDULLOBLASTOMA WHILE MAKING THEM SUSCEPTIBLE TO ANTI-CD47 INDUCED MACROPHAGE PHAGOCYTOSIS VIA NF-KB-TGM2 DRIVEN TUMOR INFLAMMATION
por: Marquardt, Viktoria, et al.
Publicado: (2023)

IMMU-08. SALVAGE IMMUNOTHERAPIES FOR REPLICATION REPAIR DEFICIENT (RRD) HIGH-GRADE GLIOMA FAILING ANTI-PD1 MONOTHERAPY: AN IRRDC REPORT
por: Das, Anirban, et al.
Publicado: (2023)

OTHER-16 DIAGNOSTIC INTERVALS IN BRAIN TUMORS IN IBADAN
por: Agboola, Oluseyi, et al.
Publicado: (2023)

NEIM-07 HARNESSING END-TO-END CLOUD-BASED WORKFLOWS AND MULTI-MODAL DATA ANALYTICS IN PEDIATRIC BRAIN TUMOR IMAGING AT THE CHILDREN’S BRAIN TUMOR NETWORK (CBTN)
por: Nabavizadeh, Ali, et al.
Publicado: (2023)

OTHER-05 THE CHALLENGES IN MANAGING CHILDREN WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMORS IN UGANDA
por: Katasi, Victoria, et al.
Publicado: (2023)

OTHER-03 A COMPARATIVE ANALYSIS OF BRAIN TUMOR PALLIATIVE CARE PRACTICES IN CAMEROON AND NIGERIA
por: Tadipatri, Ramya, et al.
Publicado: (2023)

OTHER-02 BRAIN TUMORS: CLINICAL PRESENTATION AT THE NATIONAL CENTER FOR NEUROLOGICAL SCIENCES IN KHARTOUM 2019-2022
por: Nasr, Arwa, et al.
Publicado: (2023)

NEIM-13 THE PROGNOSTIC ROLE OF VENTRICULAR SIZE AND ITS DYNAMICS IN PATIENTS WITH LEPTOMENINGEAL METASTASIS FROM SOLID TUMORS
por: Le Rhun, Emilie, et al.
Publicado: (2023)

OTHER-09 RATES AND PATTERNS OF CENTRAL DIABETES INSIPIDUS AFTER SURGERY FOR SELLAR AND PARASELLAR TUMORS AT THE KENYATTA NATIONAL HOSPITAL
por: Ngetich, Gilbert, et al.
Publicado: (2023)

OTHER-04 FEASIBILITY STUDY ON BRAIN TUMOR BIOBANKING AND REGISTRY IN SUB-SAHARAN AFRICAN COUNTRIES: A QUESTIONNAIRE-BASED SURVEY
por: Odukoya, Lateef, et al.
Publicado: (2023)

CNSC-01. GABAERGIC NEURON-TO-GLIOMA SYNAPSES IN DIFFUSE MIDLINE GLIOMAS
por: Barron, Tara, et al.
Publicado: (2023)

NEIM-11 DEUTERIUM METABOLIC IMAGING (DMI) DETECTS A LARGER WARBURG EFFECT IN HIGH-GRADE BRAIN TUMORS AND IN IDH WILD TYPE GLIOMAS
por: Kim, Lauren, et al.
Publicado: (2023)

SPINAL TUMORS-03 MALIGNANT PHYLLODES TUMOR OF THE BREAST WITH METASTASIS TO THE THORACIC SPINE: A CASE REPORT
por: Xavier, Rutayisire François, et al.
Publicado: (2023)

MDB-44. A TRANSFER LEARNING APPROACH FOR AUTOMATIC SEGMENTATION OF TUMOR SUB-COMPARTMENTS AND TUMOR HABITAT IN PEDIATRIC MEDULLOBLASTOMA
por: Bareja, Rohan, et al.
Publicado: (2023)

SYST-08 ROLE OF THE MICROBIOME IN BRAIN TUMORS
por: Omer, Mohammed
Publicado: (2023)

SYST-24 PROPOFOL EXERTS ANTI-TUMOR EFFECTS IN GLIOMA AND THE TUMOR MICROENVIRONMENT VIA NON-CODING RNAS AND SECRETED EXOSOMES
por: Penning, Donald, et al.
Publicado: (2023)

PATIENT ADVOCACY-02 BRAIN TUMORS MATTER: HOW TO IMPROVE THE MANAGEMENT OF PATIENTS WITH BRAIN TUMORS AT THE CNHU HKM OF COTONOU IN BENIN?
por: Gankpe, Gbetoho Fortune
Publicado: (2023)

IMG-08. VOLUMETRIC MEASUREMENT OF TUMOR SIZE OUTPERFORMS STANDARD TWO-DIMENSIONAL METHOD IN EARLY PREDICTION OF TUMOR PROGRESSION IN PEDIATRIC GLIOMA
por: Khalili, Nastaran, et al.
Publicado: (2023)

SYST-12 LP-184, A NOVEL ACYLFULVENE-DERIVED TUMOR SITE ACTIVATED SMALL MOLECULE INHIBITS ADULT AND PEDIATRIC CNS TUMOR CELL GROWTH
por: Kulkarni, Aditya, et al.
Publicado: (2023)

PITUITARY TUMORS-01 HYPERPROLACTINEMIA AS A CLINICAL MARKER OF INVASIVE PROLACTINOMAS
por: Gankpe, Gbetoho Fortune, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a6skqr9qissoau0sart5jqd49n